Proton Pump Inhibitor Lawsuits
Numerous Proton Pump Inhibitor have been filed in the past few decades. Proton Pump Inhibitors (PPIs), which inhibit the body’s production of gastric acid, are among the most popular OTC medications readily available, and therefore are used generally to treat ailments such as acid reflux and heartburn.
It is estimated that $14 billion have been spent on PPIs each year. The initial Proton Pump Inhibitor lawsuits stated that PPI’s led to bone fractures and associated ailments by inhibiting the capacity to absorb calcium. One of the most serious claim, registered during the past few decades, is that PPI’s could lead to severe kidney condition.
Plaintiffs claimed that producers failed to notify and misled the people regarding the risks linked to the drugs. In response to adverse condition reports the FDA has issued several directives to manufacturers. In 2010 the FDA ordered manufacturers to include a warning to PPI packaging regarding calcium absorption. Four years after, in 2014, the FDA required PPI makers to include warnings to add labels regarding the possibility of acute interstitial nephritis, a serious kidney condition. PPIs include some of the most recognizable brand names in pharma and products named in lawsuits include Nexium, Prevacid and Prilosec.
Multidistrict Litigation in Proton Pump Inhibitor Lawsuits
Since August 2017, there are 194 lawsuits pending under Multidistrict Litigation (MDL) (IN RE: Proton-Pump Inhibitor Products Liability Litigation (No. II) – MDL 2789) in federal court in the District of New Jersey. Abilify cases were united with the intention of MDL to simplify and combine the lawsuit procedure.
Cases from around the state could be united in one courtroom and Judge in multidistrict litigation in order to combine and simplify pretrial discovery. If the cases aren’t settled or ignored the presiding judge and parties involved might select one or more representatives’ cases to litigate. All these “bellwether” cases provide guidance to additional plaintiffs about if and how to continue.
At the time of this consolidation into MDL there were 161 wrongful death cases in litigation.
Plaintiffs allege that defendants failed to warn of the negative effects and risks related to PPIs.” This is actually the second time that program was designed for consolidation of the PPI cases into MDL. The very first application failed in February 2017 since the panel ruling on consolidation found that there were various kidney ailments claimed, a variety of different defendants and a variety of products. In this case, the panel decided that the growing number of cases with similar statements and the rising complexity of these litigations now merited consolidation into an MDL
Proton Pump Inhibitor Uses
The FDA approved its use in 2002. It has several listed and approved uses:
- Barrett’s esophagus
- Eosinophilic esophagitis
- Stress gastritis and ulcer prevention in critical care
- Gastrinomas and other conditions that cause hypersecretion of acid including Zollinger–Ellison syndrome (often 2–3x the regular dose is required)
- Peptic ulcer disease including after endoscopic treatment for bleeding
- As part of Helicobacter pylori eradication therapy
- Gastroesophageal reflux disease (GERD or GORD) including symptomatic endoscopy-negative reflux disease and associated laryngopharyngeal reflux causing laryngitis and chronic cough
The very first PPI, Prilosec, was approved for use by the FDA in 1989.
Nowadays over 20 million individuals use over a dozen types of this drug. OTC variations are qualified for acid reflux and heartburn. Prescription forms can be prescribed for ulcers and another applications described above.